Information for patients
Patient journey
On this page you can find information about chimeric antigen receptor (CAR) T-cell therapy.
CAR T-cell therapy is a novel form of immunotherapy to treat cancer using a patient’s own T-cells which are collected via leukapheresis or T-cells from a donor. In Europe, patients can be treated with CAR T-cell therapy as part of standard of care or by participating in a clinical trial. Currently, only CAR T-cell therapies using patients’ own T-cells are available as standard of care to treat hematologic cancers in Europe (i.e. not as part of a clinical trial). Although often only a single infusion with CAR T-cells is needed, the treatment trajectory is intensive and consists of several treatment phases as displayed in the Figure below.
On this page, you can find links to existing written and audiovisual information and educational material about the CAR T-cell therapy journey and treatment phases in six different languages (Dutch, English, French, German, Italian, and Spanish). Additionally, this page includes videos from CAR T-cell experts participating in T2EVOLVE in which they introduce themselves, explain why T2EVOLVE is important for them, talk about projects they are working on and what patients can expect from this and explain a bit more about CAR T-cell treatment in Europe.
Patient material list of links by language*
Written material
The C A R T – C E L L T H E R A P Y/CLINICAL TRIAL JOURNEY: A Guide for Patients and Carers
The NA-ATTC is pleased to offer The CAR T-Cell Therapy Clinical Trial Journey – A Guide for Patients and Carers in partnership with Autolus Therapeutics. This Guide is intended for people who are either considering enrolling in or are already enrolled in a CAR T-cell therapy clinical trial. It contains information for both patients and those who care for them (92 pages).
Infographic: Mayo Clinic CAR-T Cell Therapy Program – Mayo Clinic
(2 pages)
Infographic on CAR T Cell Therapy Treatment Experience – Bristol Myers Squibb™ (bms.com)
Cell therapy treatment experience fact sheet (1 page)
Audiovisual material
Blood Cancers and CAR T-Cell Therapy – MD Anderson Cancer Center, Texas, USA
Short video (<2 minutes) explaining CAR T cell mechanism of action
The CAR T cell therapy process, step by step – Bristol Myers Squibb™
4 minute long animation explaining autologous CAR T Cell journey
What Is CAR T-Cell Therapy? – Mofitt Cancer Center
Short animation (<2 minutes) on CAR T mechanism of action
CAR T-Cell Therapy – Children’s Hospital of Philadelphia (chop.edu)
An animation for Kids (<2 minutes) followed by a visit of the immunotherapy center of the Children’s Hospital of Philadelphia
CAR T Cell – Patient Education – Huntsman Cancer Institute
Scientific Powerpoint presentation of CAR T cell (~10 minutes)
Matériel audiovisuel
Traitement des lymphomes – l’immunothérapie par cellules CAR T, les principes – Lymphosite
<6 minutes de video explicative
Matériel écrit
Sans Mario, c’est quoi les CAR‑T ? – INSERM
Une page de présentation des CAR T cells
Nouvel horizon de traitement: cellules T porteuses de recepteurs aantignes chimeriques (CAR-T) – SLLC (Société de Leucémie & Lymphome du Canada)
Thérapie cellulaire CAR-T – l’Hôpital d’Ottawa
40 pages d’explication du traitement par CAR T cells dont deux annexes 1. Information et soutien pour le patient et son aidant naturel – 2. Guide de nutrition
*This list is not exhaustive and is regularly updated.
The T2EVOLVE consortium followed an internal process in order to evaluate and select the material shared under the Patient material hub. This selection is limited to material freely available. T2EVOLVE consortium makes no representation or warranty as to the completeness or accuracy of the information contained herein.
T2EVOLVE Consortium member insights
In the videos below, four T2EVOLVE consortium members introduce themselves, explain why T2EVOLVE is important to them, discuss projects they are working on and what patients can expect from this, and explain a bit more about CAR T-cell treatment in Europe
Michael Hudecek
In this video, Prof Dr Michael Hudecek, clinician scientist at the University Hospital of Würzburg, Germany, T2EVOLVE Project Coordinator and Director CAR-T Research Program, Cellular Immunotherapy for Malignant Diseases Max Eder Research Group‚ CAR T-cell engineering, introduces himself and talks amongst others about the current status of CAR T-cell therapy for treatment of patients with multiple myeloma and why it is important to participate in a clinical trial.
Ulrich Jäger
In this video, Prof Dr Ulrich Jäger, hematologist at the Medical University of Vienna and Head of the clinical department for hematology and hemostaseology at Vienna General Hospital, Vienna, Austria, introduces himself and talks about the current indications for commercially available CAR T-cell therapy, reasons for not being eligible for CAR T-cell therapy if you have the correct indication, and how T2EVOLVE helps with the development of this new treatment.
Marie José Kersten
In this video, Prof Dr Marie José Kersten, hematologist at Amsterdam University Medical Centers and co-founder of LYMMCARE (Lymphoma and Myeloma Center Amsterdam) and the Dutch LLPC consortium which is focused on performing early clinical studies in the Netherlands, introduces herself and talks amongst others about quality of life and long-term toxicity (side effects) after CAR T-cell therapy.
Elise Pennings
In this video, Elise Pennings, PhD student at Amsterdam University Medical Centers and Erasmus School of Health Policy and Management, Erasmus University Rotterdam, the Netherlands, introduces herself and talks about the current situation regarding access to CAR T-cell therapy in Europe and how patients can get involved in the T2EVOLVE project.
